Skip to content

Trial Summary

This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety, tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).



ACTRN/NCT /ethics:


Scientific title:

Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia

Sponsor / Cooperative group:

K-Group Alpha, Inc.

Trial & Patient Characteristics

Cancer TypeNon-Hodgkin Lymphoma; Acute Myeloid Leukemia
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2020-10-13
Anticipated End Date2023-05-01

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorDr Akash Kalro
Recruitment StatusRecruiting